



SagaStandards: Revolutionizing Pharma

An Initiative to Shape the Future of
Pharmaceuticals





Why Pharma Needs Change

- ❖ Global market: \$1.5T, growing to \$3.1T by 2032.
- ❖ Challenges:
 - ❖ Fraud: \$10B-\$20B in counterfeit drugs yearly.
 - ❖ Trials: \$6B wasted on data inefficiencies.
 - ❖ Compliance: \$30B in regulatory delays.
 - ❖ Silos: \$2B-\$3B in redundant research.
- ❖ Solution: Standardized organizer and global persistent state data management.

Global market
growing to \$3.1T by 2032

Losses


\$1.5T

vs

\$100B

\$6B Trials

Global market




Solution



Leading Pharma Transformation

- ❖ Mission: Implement open standards for tokenized pharma assets.
- ❖ Initiative: Global class tree with CDISC, USP, ISO, GS1, ISPE.
- ❖ SagaChain Features:
 - ❖ SagaPSA: Automated, flexible assets.
 - ❖ Persistent State: Live, auditable data.
 - ❖ Sharding: 4 shards, scales to 5,000.
- ❖ Demo: sagascan.prasaga.com


SagaChain Architecture





The Global Class Tree Explained

- ❖ Hierarchical schema for assets (drugs, trials).
- ❖ Features:
 - ❖ Extensible: Multi-inheritable SagaPSA (e.g., “Vaccine”).
 - ❖ Interoperable: Aligns with SDO standards.
 - ❖ Persistent: Live data (e.g., “TrialStatus: Phase 3”).
- ❖ Example: “PharmaceuticalAsset” → “Drug” → “Tablet”.





Why SagaChain Stands Out

- ❖ SagaChain:
 - ❖ Up to 33k+ TPS (500+ shards) on MainNet.
 - ❖ SagaPSA: Flexible, automated logic.
 - ❖ Persistent State: Real-time accuracy.
- ❖ Vs. Ethereum: Slow (30 TPS), costly.
- ❖ Vs. Solana: No object model.
- ❖ Vs. Hyperledger: Not public-scalable.
- ❖ Proof: Public Development Testnet 4-shards






Saving \$60B-\$122B Annually

- ❖ Supply Chain: \$5B-\$16B (50-80% fraud cut).
- ❖ Trials: \$30B (20% cost reduction).
- ❖ Compliance: \$9B (30% audit savings).
- ❖ Data Sharing: \$1B-\$1.5B (50% redundancy cut).
- ❖ Operations: \$15B-\$45B (5-10% savings).

Saving \$60B-\$122B Annually






Adding \$225B-\$375B in Revenue

- ❖ Market Expansion: \$50B-\$75B (emerging markets).
- ❖ Faster Approvals: \$50B-\$100B (6-12 months).
- ❖ New Models: \$75B-\$150B (tokenized IP).
- ❖ Total: \$285B-\$497B (19-33% of \$1.5T).

Adding \$225B-\$375B in Revenue

- Market Expansion (emerging markets)
- Faster Approvals (6-12 months)



Total: \$285B-\$497B 19-33% of \$1.5T



Transforming Lives and Systems

- ❖ Patient Safety: 100,000+ lives saved from counterfeits.
- ❖ Regulatory Trust: Instant FDA/EMA audits.
- ❖ Global Access: Drugs for 2B underserved.
- ❖ Sustainability: 5-10% carbon cut (50M tons CO2).



SAFETY



TRUST



ACCESS




SUSTANBILITY





Implementing CDISC

- ❖ Role: Clinical trial standards (SDTM, CDASH).
- ❖ Alignment: “ClinicalTrial” SagaPSA map to SDTM.
- ❖ Impact: \$30B trial savings, faster approvals.
- ❖ SagaChain: Live data, sharding scales.
- ❖ Call: Shape trial standards

SDTM Mapping



SagaPSA



Implementing USP

- ❖ Role: Drug quality standards.
- ❖ Alignment: “Drug” SagaPSA embed classifications.
- ❖ Impact: \$5B-\$16B fraud reduction.
- ❖ SagaChain: Persistent state ensures trust.
- ❖ Call: Standardize tokenized drugs.






ISO Alignment

- ❖ Role: ISO 11238 for medicinal products.
- ❖ Alignment: “MedicinalProduct” SagaPSA.
- ❖ Impact: \$1B-\$1.5B data sharing savings.
- ❖ SagaChain: Sharding scales globally.
- ❖ Call: Join TC 215 for standards.

ISO 11238 standard to SagaPSA





Implementing ISPE

- ❖ Role: GMP for manufacturing.
- ❖ Alignment: “DrugProduction” SagaPSA.
- ❖ Impact: \$9B compliance savings.
- ❖ SagaChain: SagaOS automates audits.
- ❖ Call: Define manufacturing standards.

TOKENIZED FACTORY





Benefits for Government

- ❖ Transparency: Instant audits via explorer.
- ❖ Compliance: Aligns with FDA/EMA.
- ❖ Safety: Saves 100,000+ lives.
- ❖ Global Impact: Access for 2B people.



TRANSPARENCY



COMPLIANCE



SAFETY



Why Industry Should Join

- ❖ Savings: \$60B-\$122B annually.
- ❖ Revenue: \$225B-\$375B yearly.
- ❖ Innovation: Tokenized IP, financing.
- ❖ Leadership: Pioneer \$3.1T market.

Tokenized IP Financing


Projected Savings **\$60B-\$122B** Annually yearly
Revenue of **\$225B-\$375B** \$3.1T market





Why Non-Profits Should Join

- ❖ Equity: Drug access for 2B underserved.
- ❖ Impact: Save lives, reduce fraud.
- ❖ Collaboration: Work with FDA, industry.
- ❖ Influence: Shape global standards.



EQUITY



IMPACT



COLLABORATION



Join the Effort

- ❖ Goal: Build class tree with SDOs.
- ❖ Tasks:
 - ❖ Define SagaPSA (e.g., “Drug”).
 - ❖ Map to CDISC, GS1, etc.
 - ❖ Pilot tokenized assets by 2026.
- ❖ Timeline: Draft 2026, Pilot: 2027/28, Adoption: 2030 and beyond.
- ❖ Contact: sagastandards@prasaga.com



A Tokenized Vaccine

- ❖ Scenario: \$500M vaccine program.
- ❖ Execution: “Vaccine” SagaPSA saves \$10M fraud.
- ❖ Compliance: \$30M audit savings.
- ❖ Revenue: \$500M from faster approval
- ❖ Stakeholders: Agencies, industry, non-profits win






Preparing for a \$3.1T Market

- ❖ Current: 4 shard public development testnet.
- ❖ Future: up to 500+ shards, 33k+ TPS on MainNet.
- ❖ Impact: Scales trials, supply chains.
- ❖ Demo: sagascan.prasaga.com
- ❖ Code: code.prasaga.com/sagachain
- ❖ Contact: sagastandards@prasaga.com


Shard/TPS Growth





Join SagaStandards Today

- ❖ Lead the \$1.5T-\$3.1T pharma revolution.
- ❖ Actions:
 - ❖ Email: sagastandards@prasaga.com
 - ❖ Explore: www.prasaga.com
 - ❖ Public Development Testnet: view: sagascan.prasaga.com
 - ❖ Deploy: sagascan.prasaga.com/client
 - ❖ Build: code.prasaga.com/sagachain



Citations

Grand View Research. (2024). Pharmaceutical Market Size & Share | Industry Report, 2030. <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report>

Statista. (2024). Global pharmaceutical industry - statistics & facts. <https://www.statista.com/topics/1764/global-pharmaceutical-industry/>

PraSaga. (2025). SagaChain Explorer. <https://sagascan.prasaga.com>

Ethereum. (2024). Ethereum Network Metrics. <https://ethereum.org>

Solana. (2024). Solana Network Performance. <https://solana.com>

WHO. (2024). Substandard and falsified medical products. <https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products>

Contact: sagastandards@prasaga.com



Citations

- McKinsey. (2023). Emerging from disruption: The future of pharma operations strategy. <https://www.mckinsey.com/capabilities/operations/our-insights/emerging-from-disruption-the-future-of-pharma-operations-strategy>
- IQVIA. (2024). The Global Use of Medicines 2024: Outlook to 2028. <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028>
- PhRMA. (2024). Industry research insights. [URL not provided; use PhRMA annual report]
- WHO. (2024). Access to medicines. <https://www.who.int/news-room/fact-sheets/detail/access-to-medicines>

Contact: sagastandards@prasaga.com



